INT164148

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 0.28
Pain Relevance 0.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Prkaca) Golgi apparatus (Prkaca) plasma membrane (Prkaca)
nucleus (Prkaca) protein complex (Prkaca) kinase activity (Prkaca)
Prkaca (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 50 99.48 Very High Very High Very High
agonist 86 96.00 Very High Very High Very High
Inflammation 10 33.20 Quite Low
withdrawal 2 5.00 Very Low Very Low Very Low
cerebral cortex 1 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
b2 receptor 1 5.00 Very Low Very Low Very Low
Kinase C 1 5.00 Very Low Very Low Very Low
Dopamine 1 5.00 Very Low Very Low Very Low
COX2 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Obesity 51 98.64 Very High Very High Very High
Disorder Of Lipid Metabolism 21 52.32 Quite High
Nociception 2 50.00 Quite Low
Stress 3 48.72 Quite Low
INFLAMMATION 9 33.20 Quite Low
Atherosclerosis 7 27.28 Quite Low
Adenocarcinoma 9 5.00 Very Low Very Low Very Low
Endometriosis (extended) 8 5.00 Very Low Very Low Very Low
Cancer 7 5.00 Very Low Very Low Very Low
Cardiovascular Disease 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The signalling pathways were pharmacologically investigated with the pre-administration of adenylyl cyclase (AC), cAMP-dependent protein kinase (PKA), protein kinase Cepsilon (PKCepsilon), and the extracellular signal-related kinase (ERK) inhibitors.
Negative_regulation (inhibitors) of Localization (administration) of PKA
1) Confidence 0.28 Published 2009 Journal Life Sci. Section Body Doc Link 19896488 Disease Relevance 0 Pain Relevance 0
in the presence/absence of the FP receptor antagonist (AL8810), EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227), or chemical inhibitors of PLC (U73122), PKA (4C3MQ), PKC (GF109203x), EGFR kinase (AG1478) or ERK1/2 kinase (PD98059).
Negative_regulation (inhibitors) of Localization (kinase) of PKA associated with antagonist
2) Confidence 0.04 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.32
Moreover, it is noteworthy that inhibition of adenylate cyclase or PKA does not modify the activator effect of apoA-I on apoE secretion (data not shown).
Negative_regulation (inhibition) of Localization (cyclase) of PKA
3) Confidence 0.03 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.28 Pain Relevance 0
These data concur with previous results using H-89 demonstrating that the PKA inhibitor H-89 had no effect on the homologous desensitization of TP?
Negative_regulation (inhibitor) of Localization (desensitization) of PKA
4) Confidence 0.02 Published 2007 Journal Biochim Biophys Acta Section Body Doc Link PMC2680961 Disease Relevance 0 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox